Introduction
The clinical trial landscape is undergoing a seismic shift. Traditional setup processes, long plagued by inefficiencies and delays, are being overhauled by cutting-edge technologies. This transformation is not just an improvement; it’s a necessity for an industry facing mounting pressure to deliver faster, more cost-effective results.
The stakes have never been higher. With the global pharmaceutical industry spending upwards of $150 billion annually on research and development, and the average cost of bringing a new drug to market exceeding $2.5 billion, the need for efficiency is paramount [1]. The COVID-19 pandemic has further highlighted the critical importance of rapid, well-organised clinical trials [2]. In this context, the adoption of advanced technologies in trial setup is not merely advantageous—it’s imperative for remaining competitive and responsive to global health needs.
Moreover, the complexity of modern clinical trials continues to increase. Adaptive trial designs, precision medicine approaches, and the rise of rare disease research all contribute to a more intricate trial landscape [3]. Traditional setup methods are simply not equipped to handle these complexities efficiently, making technological innovation not just beneficial, but essential for the future of clinical research.
The Current State of Clinical Trial Setup
Before delving into the technological advancements revolutionising clinical trial setup, it’s crucial to understand the current state of affairs. Traditionally, setting up a clinical trial has been a time-consuming and labour-intensive process, often taking months to complete. This process typically involves multiple stages, each with its own set of challenges:
- Protocol Development: This initial stage involves crafting a detailed plan for the trial, including study objectives, design, methodology, and statistical considerations. Traditionally, this has been a manual process involving multiple stakeholders and numerous revisions [4].
- Site Selection and Initiation: Identifying suitable research sites, conducting feasibility assessments, and initiating selected sites is a complex process that has historically relied heavily on manual data collection and analysis [5].
- Regulatory Submissions: Preparing and submitting regulatory documents to ethics committees and regulatory bodies is a critical step that has been prone to delays due to the volume and complexity of required documentation [6].
- Document Management: Managing the vast array of documents required for a clinical trial, including protocols, informed consent forms, and case report forms, has traditionally been a logistical challenge [7].
- Patient Recruitment: Identifying and enrolling suitable participants for a trial is often cited as one of the most significant challenges in clinical research, with traditional methods struggling to meet recruitment targets efficiently [8].
These traditional processes, while thorough, are often plagued by inefficiencies, delays, and increased costs. The need for a more streamlined, efficient approach has never been more apparent, setting the stage for the technological revolution in clinical trial setup.
Protocol Development: From Manual to Intelligent
Protocol development, the bedrock of any clinical trial, has remained stubbornly archaic until recently. The introduction of AI-assisted writing tools and centralised information systems marks a decisive break from the past [9]. Platforms like Axcelerant’s Momentum exemplify this new approach, leveraging AI to generate protocol text based on systematically gathered information. This shift from manual drafting to intelligent, prompt-driven content creation is set to dramatically accelerate the protocol development process.
The implications of this shift are profound. Traditionally, protocol development could take months, involving multiple rounds of revisions and input from various stakeholders [10]. This process was not only time-consuming but also prone to inconsistencies and errors. With AI-assisted tools, initial drafts can be generated in a matter of days, if not hours. These drafts are not only faster to produce but also more consistent and comprehensive [11].
Furthermore, the use of centralised information systems in protocol development facilitates better collaboration among team members. Instead of passing documents back and forth via email, stakeholders can work on a single, live environment, saving updates as they are made. This not only speeds up the review process but also reduces the risk of version control issues that often plague traditional methods. The result is a more streamlined, efficient protocol development process that can significantly reduce the time from concept to trial initiation [12].
AI-assisted protocol development also offers the potential for improved protocol quality. By leveraging vast databases of historical trial data, these systems can suggest optimal study designs, inclusion/exclusion criteria, and endpoint selections based on successful past trials in similar therapeutic areas [13]. This data-driven approach not only speeds up the process but also increases the likelihood of developing a robust, effective protocol.
The End of Document Chaos
The document generation phase of trial setup has historically been a quagmire of inefficiency. The industry’s move towards automated systems is not just welcome; it’s overdue. Platforms utilising pre-formatted templates and centralised data repositories are eliminating redundant work and slashing error rates. The ability to propagate changes across all related documents automatically is particularly crucial for managing the complex web of trial documentation [14].
Consider the sheer volume of documents required for a typical clinical trial: protocols, informed consent forms, participant information sheets, cover letters, summary sheets, and numerous regulatory submissions. In the past, changes to one document often meant manual updates to dozens of others, a process both time-consuming and error-prone. Automated systems now ensure that a change made in one place is reflected across all relevant documents, maintaining consistency and dramatically reducing the risk of discrepancies [15].
This automation extends beyond mere document updates. Advanced systems can now perform intelligent cross-referencing, ensuring that all parts of the trial documentation are in harmony. For instance, if the dosing regimen is changed in the protocol, the system can flag potential impacts on the informed consent form, case report forms, and even the statistical analysis plan. This level of intelligent document management not only saves time but also enhances the overall quality and coherence of trial documentation [16].
Moreover, these advanced document management systems are incorporating natural language processing (NLP) capabilities. NLP allows the system to understand and analyze the content of documents, enabling features such as automatic keyword extraction, document classification, and even compliance checking against regulatory guidelines [17]. This not only speeds up the document review process but also helps ensure regulatory compliance from the outset.
Quantifiable Efficiency Gains
While the industry awaits comprehensive data on the impact of these new technologies, early indicators point to substantial time and cost savings. The streamlining of document creation and the elimination of redundant data entry are set to compress trial setup timelines significantly. Moreover, the consistency ensured by these systems promises to smooth regulatory pathways and minimise costly delays [18].
Preliminary reports from early adopters of these technologies suggest time savings of up to 50% in document preparation and up to 30% reduction in overall setup time for clinical trials [19]. These efficiency gains are not merely about speed; they also translate to significant cost savings. Considering that the setup phase can account for a substantial portion of a trial’s budget, the financial implications of these improvements are considerable.
Furthermore, the impact of these efficiency gains extends beyond the immediate setup phase. Faster setup times mean that trials can begin enrolling patients sooner, potentially leading to earlier completion of studies. In the pharmaceutical industry, where time to market is crucial, even a few months’ acceleration in the trial process can translate to millions in additional revenue [20]. Moreover, the improved quality and consistency of documentation can lead to smoother regulatory reviews, further reducing time to market for new treatments.
It’s important to note that these efficiency gains don’t come at the expense of quality. In fact, the automated systems and AI-assisted tools often lead to higher quality documentation with fewer errors and inconsistencies. This can result in fewer queries from regulatory bodies, further streamlining the approval process [21].
Amendments: From Headache to Streamlined Process
The ability to swiftly implement trial amendments is no longer a luxury but a necessity in today’s fast-paced research environment. The centralised approach offered by new technologies transforms what was once a labyrinthine process into a straightforward task. Changes made in one place ripple through all relevant documents, ensuring consistency and drastically reducing the risk of error [22].
The impact of this streamlined amendment process cannot be overstated. In traditional setups, implementing a significant amendment could take weeks or even months, involving multiple rounds of document updates, approvals, and resubmissions. This delay not only slowed down the trial progress but also increased costs and potentially compromised patient care if important changes were delayed. With automated systems, many amendments can now be implemented in days, if not hours [23].
Moreover, the audit trail capabilities of modern systems provide an additional layer of control and transparency. Every change is logged, attributed, and time-stamped, creating a clear record of the amendment process. This not only aids in regulatory compliance but also provides valuable insights into the evolution of the trial design. Such transparency can be invaluable in post-trial analyses and in planning future studies [24].
The streamlined amendment process also has significant implications for adaptive trial designs. These innovative trial designs, which allow for pre-specified changes based on interim data analyses, have been challenging to implement due to the complexity of managing multiple potential amendments. The new technologies make adaptive designs more feasible, potentially leading to more efficient and informative clinical trials [25].
Integration: The New Standard
While standalone solutions offer significant benefits, the future clearly lies in integrated systems. APIs that allow seamless connection with existing infrastructure are becoming standard. This integration is crucial for widespread adoption across different organisational structures and trial types [26].
The power of integration extends far beyond mere convenience. When clinical trial setup systems can communicate directly with electronic data capture (EDC) systems, clinical trial management systems (CTMS), and even electronic health records (EHRs), the potential for efficiency gains multiplies. For instance, patient recruitment can be accelerated when trial criteria can be automatically matched against EHR databases. Similarly, the integration of setup systems with CTMS can enable real-time tracking of site activation progress, allowing for more agile management of multi-site trials [27].
Furthermore, integrated systems pave the way for more sophisticated data analytics. By connecting various aspects of the trial process, from setup to execution to analysis, organisations can gain deeper insights into their clinical trial operations. This data-driven approach can inform future trial designs, help identify bottlenecks in the process, and ultimately lead to more efficient and effective clinical research [28].
The integration of these systems also facilitates a more collaborative approach to clinical research. With all stakeholders working from the same integrated platform, communication becomes more streamlined, and data silos are eliminated. This can lead to better decision-making throughout the trial process and can help break down the traditional barriers between sponsors, CROs, and research sites [29].
The Road Ahead
The integration of AI in clinical trial setup is just the beginning. The industry can expect to see blockchain technology enhancing document security and transparency, while augmented reality may revolutionise site initiation and training. These advancements will inevitably reshape the role of clinical research professionals, shifting focus from administrative tasks to strategic decision-making [30].
Blockchain technology, in particular, holds immense promise for the future of clinical trials. Its ability to create immutable, transparent records could transform how we manage trial data, from patient consent to results reporting. Imagine a system where every data point, every protocol change, and every patient interaction is recorded in a tamper-proof blockchain. This could not only enhance the integrity of clinical trial data but also streamline regulatory audits and increase public trust in the clinical trial process [31].
Augmented reality (AR) is another technology poised to make significant inroads in clinical trial setup and execution. AR could revolutionise site initiation by allowing remote experts to guide local staff through complex procedures in real-time. It could also enhance patient education and consent processes, providing interactive, easily understandable explanations of trial procedures and risks. As these technologies mature, we can expect to see a shift towards more decentralised, patient-centric trial models that could significantly expand access to clinical research [32].
Looking further into the near future, we may see the emergence of virtual trials and decentralised trials where much of the trial process, from recruitment to data collection, is conducted remotely. This could dramatically reduce the geographical barriers to trial participation and potentially accelerate the drug development process even further [33].
Conclusion
The digitalisation of clinical trial setup is not a trend; it’s the new reality. Platforms like Momentum are at the vanguard of this change, offering efficiencies that were unimaginable just a few years ago. For organisations involved in clinical research, adopting these technologies is no longer optional. Those who fail to embrace this digital revolution risk being left behind in an increasingly competitive and fast-paced industry [34].
The message is clear: the future of clinical trials is here, and it’s digital. The potential benefits in terms of speed, cost, and quality are too significant to ignore. As the industry continues to evolve, it will be those who adapt quickest to these new technologies who will lead the way in bringing life-changing treatments to patients faster than ever before [35].
The transformation of clinical trial setup through technology is not just about improving processes; it’s about reimagining the entire paradigm of clinical research. By reducing administrative burdens, enhancing data quality, and accelerating timelines, these advancements have the potential to dramatically increase the number and diversity of clinical trials that can be conducted. This could lead to a broader range of treatments being studied, including for rare diseases and underserved populations that have historically been neglected in clinical research [36].
Moreover, as these technologies mature and become more widely adopted, we can expect to see a democratisation of clinical research. Smaller organisations and academic institutions, previously hampered by the high costs and complex logistics of trial setup, may find themselves better able to conduct high-quality clinical studies. This could lead to a more diverse, dynamic clinical research ecosystem, fostering innovation and accelerating the pace of medical discovery [37].
In conclusion, the technological revolution in clinical trial setup is not just changing how we conduct trials; it’s expanding what’s possible in clinical research. As we look to the future, it’s clear that embracing these technologies is not just about staying competitive—it’s about unlocking the full potential of clinical research to improve human health on a global scale. The journey has just begun, and the possibilities are limitless [38].
References:
[1] DiMasi, J. A., Grabowski, H. G., & Hansen, R. W. (2016). Innovation in the pharmaceutical industry: New estimates of R&D costs. Journal of Health Economics, 47, 20-33.
[2] Ledford, H. (2020). Coronavirus shuts down trials of drugs for multiple other diseases. Nature, 580(7801), 15-16.
[3] Woodcock, J., & LaVange, L. M. (2017). Master protocols to study multiple therapies, multiple diseases, or both. New England Journal of Medicine, 377(1), 62-70.
[4] Getz, K. A., & Campo, R. A. (2017). Trial watch: Trends in clinical trial design complexity. Nature Reviews Drug Discovery, 16(5), 307.
[5] Harper, B., & Christison, N. (2012). Fixing the protocol feasibility process. Journal of Clinical Research Best Practices, 8(1), 1-6.
[6] Nair, S. C., & Ibrahim, H. (2015). Informed consent form challenges for genetic research in a developing country like India. Journal of Clinical Research & Bioethics, 6(3), 1.
[7] Zozus, M. N., et al. (2017). Factors affecting the quality of clinical documentation for data reuse in clinical research: A systematic review. Journal of the American Medical Informatics Association, 24(5), 989-997.
[8] Carlisle, B., et al. (2015). Unsuccessful trial accrual and human subjects protections: An empirical analysis of recently closed trials. Clinical Trials, 12(1), 77-83.
[9] Harrer, S., Shah, P., Antony, B., & Hu, J. (2019). Artificial Intelligence for Clinical Trial Design. Trends in Pharmacological Sciences, 40(8), 577-591.
[10] Getz, K. A., et al. (2018). The Impact of Protocol Amendments on Clinical Trial Performance and Cost. Therapeutic Innovation & Regulatory Science, 52(6), 673-679.
[11] Shah, P., et al. (2019). Artificial intelligence and machine learning in clinical development: a translational perspective. NPJ Digital Medicine, 2(1), 1-5.
[12] Lamberti, M. J., Wilkinson, M., Harper, B., Morgan, C., & Getz, K. A. (2018). Assessing Study Start-up Practices, Performance, and Perceptions Among Sponsors and Contract Research Organizations. Therapeutic Innovation & Regulatory Science, 52(5), 572-578.
[13] Kang, J. S., Jang, I., & Cho, J. (2019). Artificial intelligence in the clinical trial design. Translational and Clinical Pharmacology, 27(1), 8-16.
[14] Meeker-O’Connell, A., et al. (2016). Enhancing clinical evidence by proactively building quality into clinical trials. Clinical Trials, 13(4), 439-444.
[15] Houston, L., Probst, Y., & Martin, A. (2018). Assessing data quality and the variability of source data verification procedures in clinical trial sites. Trials, 19(1), 203.
[16] Krishnankutty, B., et al. (2012). Data management in clinical research: An overview. Indian Journal of Pharmacology, 44(2), 168-172.
[17] Zhu, C., et al. (2019). Clinical text classification with rule-based features and knowledge-guided convolutional neural networks. BMC Medical Informatics and Decision Making, 19(3), 71.
[18] Lamberti, M. J., & Getz, K. A. (2015). Profiles of New Approaches to Improving the Efficiency and Performance of Pharmaceutical Drug Development. Tufts Center for the Study of Drug Development.
[19] Getz, K. A., & Campo, R. A. (2018). New benchmarks characterizing growth in protocol design complexity. Therapeutic Innovation & Regulatory Science, 52(1), 22-28.
[20] Schuhmacher, A., Gassmann, O., & Hinder, M. (2016). Changing R&D models in research-based pharmaceutical companies. Journal of Translational Medicine, 14(1), 105.
[21] Meeker-O’Connell, A., & Glessner, C. (2018). Clinical trial quality: From design to publication. Therapeutic Innovation & Regulatory Science, 52(4), 431-440.
[22] Getz, K. A., et al. (2016). The impact of protocol amendments on clinical trial performance and cost. Therapeutic Innovation & Regulatory Science, 50(4), 436-441.
[23] Neuer, A., Warnock, N., & Slezinger, E. (2010). The upfront cost hurdle of EDC and the eClinical transformation. Applied Clinical Trials, 19(10), 42-52.
[24] Kleppinger, C. F., & Ball, L. K. (2010). Building quality in clinical trials with use of a quality systems approach. Clinical Infectious Diseases, 51(Supplement_1), S111-S116.
[25] Thorlund, K., et al. (2018). Key design considerations for adaptive clinical trials: a primer for clinicians. BMJ, 360, k698.
[26] Ohmann, C., et al. (2017). Sharing and reuse of individual participant data from clinical trials: principles and recommendations. BMJ Open, 7(12), e018647.
[27] De Moor, G., et al. (2015). Using electronic health records for clinical research: the case of the EHR4CR project. Journal of Biomedical Informatics, 53, 162-173.
[28] Hume, S., et al. (2016). A platform for leveraging next generation sequencing for routine clinical use. AMIA Summits on Translational Science Proceedings, 2016, 111.
[29] Cutler, D. M., Nikpay, S., & Huckman, R. S. (2020). The business of medicine in the era of COVID-19. JAMA, 323(20), 2003-2004.
[30] Knepper, T. C., & McLeod, H. L. (2018). When will clinical trials finally reflect diversity?. Nature, 557(7704), 157-159.
[31] Nugent, T., Upton, D., & Cimpoesu, M. (2016). Improving data transparency in clinical trials using blockchain smart contracts. F1000Research, 5, 2541.
[32] Sharma, A., et al. (2019). Using digital health technology to better generate evidence and deliver evidence-based care. Journal of the American College of Cardiology, 73(23), 2996-3008.
[33] Inan, O. T., et al. (2020). Digitizing clinical trials. NPJ Digital Medicine, 3(1), 1-7.
[34] Fogel, D. B. (2018). Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: a review. Contemporary Clinical Trials Communications, 11, 156-164.
[35] Tenaerts, P., Madre, L., & Archdeacon, P. (2018). A decade of the Clinical Trials Transformation Initiative: What have we accomplished? What have we learned?. Clinical Trials, 15(4), 360-365.
[36] Mundi, R., et al. (2019). The COVID-19 pandemic: New concerns and connections between eHealth and digital orthopaedics. Journal of Bone and Joint Surgery, 102-A(13), e69.
[37] Lamberti, M. J., et al. (2019). A study on the application and use of artificial intelligence to support drug development. Clinical Therapeutics, 41(8), 1414-1426.
[38] Topol, E. J. (2019). High-performance medicine: the convergence of human and artificial intelligence. Nature Medicine, 25(1), 44-56.